Skip to main content Accessibility help
×
Home

Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities

  • Chris Henshall (a1), Logan Mardhani-Bayne (a2), Katrine B. Frønsdal (a3) and Marianne Klemp (a4)

Abstract

Background: The relationship between regulatory approval on the one hand and health technology assessment (HTA) and coverage on the other is receiving growing attention. Those responsible for regulatory approval, HTA, and coverage have different missions and their information requirements reflect these. There is nonetheless an increasingly popular view that improved communication and coordination between these functions could allow them all to be undertaken effectively with a lower overall burden of evidence requirements, thus speeding patient access to new products and reducing unnecessary barriers to innovation. This study summarizes the main points emerging from a recent discussion of this topic at the HTAi Policy Forum.

Results and Conclusions: After considering the roles of the various bodies, stakeholder perspectives and some current practical initiatives, those present at the Forum meeting discussed possible goals and challenges for improved interactions—in general and at specific stages of the product development life cycle. Opportunities for progress were seen in: continuing the dialogue to promote understanding and interaction between the different bodies and stakeholders; working to align scientific advice for manufacturers on the design and data requirements of pre- and post-marketing evaluation of products (specifically phase 2/3 and phase 4 trials for drugs); and extending the current dialogue to include discussion of product development to address unmet health needs.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Interactions between health technology assessment, coverage, and regulatory processes: Emerging issues, goals, and opportunities
      Available formats
      ×

Copyright

References

Hide All
1. Breckenridge, A, Woods, K, Walley, T. Medicines regulation and health technology assessment. Clin Pharmacol Ther. 2010;87:152154.
2. Chatham House. http://www.chathamhouse.org.uk (accessed March 2011).
3. Eichler, H, Bloechl-Daum, B, Abadie, E, et al. Relative efficacy of drugs: An emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov. 2010;9:277291.
4. European Medicines Agency (EMA). http://www.ema.europa.eu (accessed March 2011).
5. European Union Commission's Directives for Medical devices. http://ec.europa.eu/consumers/sectors/medical-devices (accessed March 2011).
6. European Union High Level Pharmaceutical Forum. High level pharmaceutical forum 2005–2008 final report. Core principles on relative effectiveness. http://ec.europa.eu/pharmaforum/docs/ev_20081002_frep_en.pdf (accessed March 2011).
7. Global Harmonization Task Force (GHFT). http://www.ghtf.org (accessed March 2011).
8. Health Technology Assessment International (HTAi). http://www.htai.org (accessed March 2011)
9. Health Technology Assessment International (HTAi) and the International Network of Agencies for Health Technology Assessment (INAHTA). HTA glossary. http://www.htaglossary.net (accessed March 2011).
10. Health Technology Assessment International (HTAi). Policy forum. http://www.htai.org/index.php?id=643 (accessed March 2011).
11. Hutton, J, Trueman, P, Facey, K. Harmonisation of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511517.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). http://www.ich.org (accessed March 2011).
13. International Network of Agencies for Health Technology Assessment (INAHTA). http://www.inahta.org (accessed March 2011).
14. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). http://www.ispor.org (accessed March 2011).
15. Progressive Licensing Project, Health Canada. http://www.hc-sc.gc.ca/dhp-mps/homologation-licensing/plfs_hpfd-eng.php (accessed March 2011).

Keywords

Type Description Title
EXCEL
Supplementary materials

Henshall et al. supplementary material
Supplementary table

 Excel (34 KB)
34 KB

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed